Repurposing of natural agents and their metabolites as lead compounds for new BRD9-targeting antagonists would provide an avenue for future intervention in the clinical setting, and a strong rationale to continue investigation into dietary strategies for CRC prevention. This evidence concerns the gene BRD9 and colorectal carcinoma.